Covered recipient · General Payments record
ERIC D REINES
Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease
General Payments · PY2018–2024
$5,931.06
- Reported across 332 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $362.34 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $106.71 | 4 |
| SANOFI-AVENTIS U.S. LLC | $78.11 | 3 |
| Corcept Therapeutics | $32.31 | 1 |
| TOLMAR, INC. | $28.15 | 2 |
| Xeris Pharmaceuticals, Inc. | $24.09 | 1 |
| Acella Pharmaceuticals, LLC | $21.79 | 1 |
| RECORDATI_RARE_DISEASES_INC. | $20.94 | 1 |
| Novo Nordisk AS | $18.81 | 1 |
| Abbott Laboratories | $17.16 | 1 |
| Astellas Pharma US Inc | $14.27 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $17.16 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125209669 | CMS |
| Acella Pharmaceuticals, LLC | $21.79 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126635474 | CMS |
| Astellas Pharma US Inc | $14.27 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139412347 | CMS |
| Corcept Therapeutics | $32.31 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117739258 | CMS |
| Lilly USA, LLC | $26.98 | 01/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134972891 | CMS |
| Lilly USA, LLC | $25.86 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136161459 | CMS |
| Lilly USA, LLC | $22.94 | 06/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136161461 | CMS |
| Lilly USA, LLC | $30.93 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136167642 | CMS |
| Novo Nordisk Inc | $18.81 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097816246 | CMS |
| RECORDATI_RARE_DISEASES_INC. | $20.94 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139165907 | CMS |
| SANOFI-AVENTIS U.S. LLC | $26.03 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139601194 | CMS |
| SANOFI-AVENTIS U.S. LLC | $21.75 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139601168 | CMS |
| SANOFI-AVENTIS U.S. LLC | $30.33 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139601208 | CMS |
| Tolmar, Inc. | $13.86 | 02/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138719874 | CMS |
| Tolmar, Inc. | $14.29 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138719876 | CMS |
| Xeris Pharmaceuticals, Inc. | $24.09 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144594128 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.